Skip to content

Pacira BioSciences, Inc. PCRX Repayments Of Secured Debt

Repayments Of Secured Debt at other companies

Avanos Medical logo
Avanos MedicalAVNS
$2.3M0.0%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfSecuredDebt.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s repayments of secured debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s repayments of secured debt?
Pacira BioSciences, Inc. (PCRX) reported repayments of secured debt of $0 in Q1 2026.
How has Pacira BioSciences, Inc.'s repayments of secured debt changed year-over-year?
Pacira BioSciences, Inc.'s repayments of secured debt decreased by 100.0% year-over-year, from $2.81M to $0.